Anti-CD133 CAR T-cells showed inhibitory activity against potential metastatic cells in HCC, colorectal carcinoma, and pancreatic carcinoma in phase I clinical trial (Wang et al., 2018). The gene discussed is PROM1; the disease is colorectal carcinoma.